The Laboratory and the New Oral Anticoagulants

被引:52
作者
Tripodi, Armando [1 ,2 ]
机构
[1] Univ Milan, Dept Clin Sci & Community Hlth, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
[2] IRCCS Ca Granda Maggiore Hosp Fdn, Milan, Italy
关键词
DIRECT THROMBIN INHIBITOR; FACTOR XA INHIBITOR; COAGULATION ASSAYS; PROTHROMBIN TIME; PLASMA-CONCENTRATIONS; DABIGATRAN ETEXILATE; RIVAROXABAN; HEPARIN; THROMBOEMBOLISM; APIXABAN;
D O I
10.1373/clinchem.2012.189704
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: The new oral anticoagulants (NOAs) dabigatran, rivaroxaban, and apixaban have proved effective and safe when used in clinical trials, without a need to adjust the dose in response to laboratory testing. This demonstrated efficacy does not necessarily mean that the laboratory, considered the mainstay for the management of the old anticoagulants, will no longer play a role in treatment with NOAs. CONTENT: Laboratories are involved in the management of anticoagulants in 2 ways. The first, monitoring, implies laboratory testing to assess the drug's effect and to adjust the dosage to maintain anticoagulation within the therapeutic interval. This consideration applies to the old drugs. The second way, measurement, implies laboratory evaluations of drug effect to determine whether patients are under-or over-anticoagulated, information that can be useful for decision-making in special circumstances. The latter applies to NOAs. SUMMARY: Measurements of the effect of NOAs are indicated in several situations: (a) patients with adverse events (i.e., thrombotic/hemorrhagic), particularly those who present with overdosage owing to excessive drug intake or decreased clearance; (b) patients undergoing surgical procedures for ensuring that no residual drug remains in the circulation; (c) patients requiring anticoagulation reversal because of life-threatening hemorrhage; (d) patients with renal insufficiency, who are likely to accumulate the drug in the circulation; (e) patients with liver failure, because NOAs are metabolized by the liver; (f) patients taking other drugs that might increase/decrease the effects of NOAs via drug-drug interactions. The choice of tests is based on such characteristics as availability, linearity of the dose-response curve, standardization, and responsiveness to increasing drug dosage. Practitioners need to be aware that NOAs can interfere with the measurement of common hemostasis parameters. (C) 2012 American Association for Clinical Chemistry
引用
收藏
页码:353 / 362
页数:10
相关论文
共 33 条
[1]   Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay [J].
Barrett, Yu Chen ;
Wang, Zhaoqing ;
Frost, Charles ;
Shenker, Andrew .
THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) :1263-1271
[2]   PROSPECTIVE STUDY OF VALUE OF MONITORING HEPARIN TREATMENT WITH ACTIVATED PARTIAL THROMBOPLASTIN TIME [J].
BASU, D ;
CADE, J ;
GALLUS, A ;
HIRSH, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1972, 287 (07) :324-+
[3]   Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor [J].
Becker, Richard C. ;
Yang, Hongqiu ;
Barrett, Yuchen ;
Mohan, Puneet ;
Wang, Jessie ;
Wallentin, Lars ;
Alexander, John H. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 32 (02) :183-187
[4]   Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome [J].
Becker, Richard C. ;
Alexander, John H. ;
Newby, L. Kristin ;
Yang, Hongqiu ;
Barrett, Yuchen ;
Mohan, Puneet ;
Wang, Jessie ;
Harrington, Robert A. ;
Wallentin, Lars C. .
THROMBOSIS AND HAEMOSTASIS, 2010, 104 (05) :976-983
[5]   Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology [J].
Cushman, M ;
Tsai, AW ;
White, RH ;
Heckbert, SR ;
Rosamond, WD ;
Enright, P ;
Folsom, AR .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 (01) :19-25
[6]   FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C [J].
DAHLBACK, B ;
CARLSSON, M ;
SVENSSON, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) :1004-1008
[7]   Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate [J].
Douxfils, Jonathan ;
Mullier, Francois ;
Robert, Severine ;
Chatelain, Christian ;
Chatelain, Bernard ;
Dogne, Jean-Michel .
THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) :985-997
[8]   Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].
Eerenberg, Elise S. ;
Kamphuisen, Pieter W. ;
Sijpkens, Meertien K. ;
Meijers, Joost C. ;
Buller, Harry R. ;
Levi, Marcel .
CIRCULATION, 2011, 124 (14) :1573-1579
[9]   Heparin and low-molecular-weight heparin [J].
Gray, Elaine ;
Mulloy, Barbara ;
Barrowcliffel, Trevor W. .
THROMBOSIS AND HAEMOSTASIS, 2008, 99 (05) :807-818
[10]   Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests [J].
Halbmayer, Walter-Michael ;
Weigel, Guenter ;
Quehenberger, Peter ;
Tomasits, Josef ;
Haushofer, Alexander C. ;
Aspoeck, Gerold ;
Loacker, Lorin ;
Schnapka-Koepf, Mirjam ;
Goebel, Georg ;
Griesmacher, Andrea .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (09) :1601-1605